Váncsa, Andrea and Gergely, Lajos and Ponyi, Andrea and Lakos, Gabriella and Nemeth, Júlia and Dankó, Katalin (2010) Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. JOINT BONE SPINE, 77 (2). pp. 125-130. ISSN 1297-319X
![]() |
Text
1_s2.0_S1297319X10000114_main_u.pdf Restricted to Repository staff only Download (223kB) | Request a copy |
Abstract
OBJECTIVE: The current study was performed in order to determine the prevalence of different myositis-specific and myositis-associated antibodies, as well as their association with clinical characteristics, disease course and response to therapy in 169 Hungarian patients with idiopathic inflammatory myopathy. METHODS: Sera of 130 primary and 39 overlap myositis including systemic sclerosis (13), rheumatoid arthritis (12), systemic lupus erythematosus (5) and Sjogren's syndrome (9) cases were analyzed. Antinuclear antibody, scleroderma-associated antibodies (anti-centromere, anti-topoisomerase I), anti-Jo-1, anti-PL-7, anti-PL-12, anti-Mi-2, anti-SRP and anti-PM-Scl, anti-Ku, anti-SS-A, anti-SS-B, anti-U1snRNP were tested. Autoantibody results were compared with clinical characteristics, disease course of overlap versus primary myositis patients, as well as with response to therapy. RESULTS: Associated connective tissue disease occurred in 23.1% of the patients. Myositis-associated antibodies were found in 8.5% of primary myositis patients, indicating that 11 additional primary myositis patients (23% vs. 29.6%) can be classified as overlap in all cohort according to the newly proposed diagnostic criteria. Polymyositis was found to be the most common myositis form in overlap myositis (87.2%), while scleroderma was the most common disease associated (33.3%). ANA was positive in 25.4% of primary and in 61.5% of overlap myositis cases. Altogether 39.6% of myositis patients (n=67) had autoantibodies, most commonly anti Jo-1 (18.3%) correlating with a polycyclic disease course. CONCLUSION: Inclusion of myositis-specific and associated antibodies into the newly proposed diagnostic criteria for inflammatory myopathies is of great importance in order to determine subclasses and to introduce adequate therapy in time.
Item Type: | Article |
---|---|
Additional Information: | CI: Copyright 2010 Societe francaise de rhumatologie. Published by Elsevier SAS. All : rights reserved. |
Uncontrolled Keywords: | Young Adult; Treatment Outcome; Seroepidemiologic Studies; Retrospective Studies; Polymyositis/*classification/drug therapy/epidemiology/*immunology; Middle Aged; Male; Immunosuppressive Agents/therapeutic use; Humans; Follow-Up Studies; Female; Dermatomyositis/*classification/drug therapy/epidemiology/*immunology; Cross-Sectional Studies; Autoantibodies/blood/*immunology; Aged; Adult; Adolescent; egyetemen (Magyarországon) készült közlemény |
Subjects: | R Medicine / orvostudomány > R1 Medicine (General) / orvostudomány általában |
SWORD Depositor: | MTMT SWORD |
Depositing User: | MTMT SWORD |
Date Deposited: | 05 Apr 2017 12:01 |
Last Modified: | 05 Apr 2017 12:01 |
URI: | http://real.mtak.hu/id/eprint/50978 |
Actions (login required)
![]() |
Edit Item |